173 related articles for article (PubMed ID: 24170099)
1. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
Rodríguez de Vera Gómez P; Méndez Muros M; Torres Cuadro A; Toyos Sáenz de Miera FJ; López Ruiz R; Guerrero Vázquez R; García González JJ; Garrido Hermosilla AM; Martín Hernández T
J Neurol; 2024 Jan; 271(1):486-496. PubMed ID: 37773417
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease.
Ueland GÅ; Ueland HO; Stokland AM; Bhan A; Schønberg A; Sollid ST; Morgas DE; Holmøy T; Lima K; Methlie P; Løvås K; Torkildsen Ø; Husebye ES
J Clin Endocrinol Metab; 2024 Jan; 109(2):344-350. PubMed ID: 37708353
[TBL] [Abstract][Full Text] [Related]
5. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.
Baker D; Ali L; Saxena G; Pryce G; Jones M; Schmierer K; Giovannoni G; Gnanapavan S; Munger KC; Samkoff L; Goodman A; Kang AS
Front Immunol; 2020; 11():124. PubMed ID: 32117274
[TBL] [Abstract][Full Text] [Related]
6. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Barclay K; Carruthers R; Traboulsee A; Bass AD; LaGanke C; Bertolotto A; Boster A; Celius EG; de Seze J; Cruz DD; Habek M; Lee JM; Limmroth V; Meuth SG; Oreja-Guevara C; Pagnotta P; Vos C; Ziemssen T; Baker DP; Wijmeersch BV
Front Neurol; 2019; 10():253. PubMed ID: 30967831
[TBL] [Abstract][Full Text] [Related]
7. Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis.
Yang J; Sun Y; Zhou X; Zhang D; Xu Z; Cao J; Fan B
Front Immunol; 2024; 15():1343971. PubMed ID: 38690271
[TBL] [Abstract][Full Text] [Related]
8. Long-term Effect of Thyrotropin-binding Inhibitor Immunoglobulin on Atrial Fibrillation in Euthyroid Patients.
Hsu JC; Fan KC; Wang TC; Chuang SL; Chao YT; Lin TT; Huang KC; Lin LY; Lin LC
Endocr Pract; 2024 Apr; ():. PubMed ID: 38574890
[TBL] [Abstract][Full Text] [Related]
9. Glomerulonephritis after Alemtuzumab Treatment for Multiple Sclerosis: A Report of Two Cases.
Almuhaiteeb A; Alkeay K; Altaleb A
Glomerular Dis; 2024; 4(1):84-90. PubMed ID: 38660579
[TBL] [Abstract][Full Text] [Related]
10. Thyroid and Adrenal Dysfunction in Hemoglobinopathies Before and After Allogeneic Hematopoietic Cell Transplant.
Mandava M; Lew J; Tisdale JF; Limerick E; Fitzhugh CD; Hsieh MM
J Endocr Soc; 2023 Nov; 7(12):bvad134. PubMed ID: 37953902
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 AND THE THYROID FUNCTION IN PATIENTS WITH HCV- ASSOCIATED HEPATOCELLULAR CARCINOMA.
Toma L; Zgura A; Isac T; Simu R; Mercan-Stanciu A; Dodot M; Iliescu EL
Acta Endocrinol (Buchar); 2022; 18(3):392-396. PubMed ID: 36699175
[TBL] [Abstract][Full Text] [Related]
12. Graves' orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy?
Cima LN; Lambrescu IM; Stejereanu L; Colita A; Or R; Fica S
Clin Case Rep; 2018 May; 6(5):867-870. PubMed ID: 29744075
[TBL] [Abstract][Full Text] [Related]
13. Risk of Incident Thyroid Dysfunction in the Post-Acute Phase of COVID-19: A Population-Based Cohort Study in Hong Kong.
Lui DTW; Xiong X; Cheung CL; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Li L; Chung MSH; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
Endocr Pract; 2024 Mar; ():. PubMed ID: 38552902
[TBL] [Abstract][Full Text] [Related]
14. A case of relapsing anti-GBM disease secondary to alemtuzumab therapy.
Leibowitz SM; Manickam V; Srivastava V; Kan G
CEN Case Rep; 2024 Jun; 13(3):209-214. PubMed ID: 37943475
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management.
Mahzari M; Arnaout A; Freedman MS
Can J Neurol Sci; 2015 Sep; 42(5):284-91. PubMed ID: 25990097
[TBL] [Abstract][Full Text] [Related]
16. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
Tuohy O; Costelloe L; Hill-Cawthorne G; Bjornson I; Harding K; Robertson N; May K; Button T; Azzopardi L; Kousin-Ezewu O; Fahey MT; Jones J; Compston DA; Coles A
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):208-15. PubMed ID: 24849515
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.
Havrdova E; Horakova D; Kovarova I
Ther Adv Neurol Disord; 2015 Jan; 8(1):31-45. PubMed ID: 25584072
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.
Rotondi M; Molteni M; Leporati P; Capelli V; Marinò M; Chiovato L
Front Endocrinol (Lausanne); 2017; 8():254. PubMed ID: 29033895
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Hartung HP; Aktas O; Boyko AN
Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
